{"date":"2026-09-26","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-7729-2026-09-26-1702-1fbwywp","company_id":"7729","company":"仲恩生醫","market":"興櫃","industry":"生技醫療","date":"2026-09-26","time":"17:02:03","subject":"本公司授權合作夥伴公告 -本公司新藥產品Stemchymal正式獲得「再生醫療等製品製造販賣業許可(MAH)」。","clause":"第44款","fact_date":"2026-09-26","cite_as":"公開資訊觀測站重大訊息：仲恩生醫（7729），2026-09-26 17:02，「本公司授權合作夥伴公告 -本公司新藥產品Stemchymal正式獲得「再生醫療等製品製造販賣業許可(MAH)」。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}